Small cell lung cancer research and advocacy are spotlighted by new funding initiatives. Read to see emerging priorities and opportunities.
Key Takeaways
- We are open to conversations with prospective partners and investors who share our vision
- Three-year award expected to support novel treatment strategies and correlative translational research
- Progress in SCLC has lagged behind non-small cell lung cancer